Cargando…
Die Prävalenz von SARS-CoV-2-IgG-AK liegt bei 1,2%: Screening bei asymptomatischen ambulanten Patienten
Patients with newly diagnosed COVID-19 (coronavirus disease 2019) develop antibodies against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). To date, few data have been obtained of the prevalence of SARS-CoV-2-antibodies in general population and in asymptomatic outpatients in Germany....
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417847/ https://www.ncbi.nlm.nih.gov/pubmed/32780376 http://dx.doi.org/10.1007/s15006-020-0750-y |